在急性冠状动脉综合征患者中抑制XI因子
Carmelo Raffo1, Davide Capodanno1
1Cardiovascular Department, A.O.U. Polyclinic 'G. Rodolico-San Marco', University of Catania, Catania.
概括
XI因子 (FXI) 抑制剂显示出在心脏病发作后减少缺血事件的潜力,而不会增加出血风险. 像PACIFIC-AMI这样的早期试验表明FXI抑制是安全的,尽管有效性需要在更大的试验中进一步研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 急性冠状动脉综合征 (ACS) 患者具有高凝血状态,增加了复发性缺血事件.
- 目前的抗血小板和抗凝固疗法降低了缺血风险,但具有显著的出血风险.
- 十一因子 (FXI) 缺乏与血栓形成的减少和血流的减少有关,这表明FXI抑制作为治疗点.
研究的目的:
- 评估FXI抑制剂在心肌梗塞 (MI) 后的二次预防中的安全性和有效性.
- 探索FXI抑制剂的潜力,将血栓形成与血液静止脱,降低缺血风险而不会增加出血.
主要方法:
- 在PACIFIC-AMI试验中,评估了口服FXIa抑制剂阿桑德西安在MI后患者的安全性.
- 主要终点是BARC类型2,3或5出血,比较阿桑德西安剂量与安慰剂.
- 效率是一个次要的结果,该研究缺乏统计能力来得出最终的结论.
主要成果:
- 在asundexian剂量和安慰剂之间没有观察到重大出血事件的显著差异.
- 疗效数据是中立的,与该试验有限的统计能力相一致,以检测这种差异.
结论:
- 抑制FXI是急性心脏病发作患者的二次预防的一个有希望的策略.
- 在更大的第三期试验中进行进一步的研究,如LIBREXIA-ACS,对于确认FXI抑制剂的疗效至关重要.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
01:16Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
488
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
488